Oklahoma Startup Harnesses Phage Therapy to Combat Superbugs

A startup based in Stillwater, Oklahoma, is pioneering an innovative approach to combat antibiotic-resistant bacteria, commonly known as superbugs. Founded by **William Colton**, Paldara Pharmaceuticals is developing a phage therapy that utilizes naturally occurring viruses to target and eliminate harmful bacteria like **E. coli**.

In a small laboratory at the **Meridian Technology Center**, Colton works with inert samples of bacteria that have adapted rapidly, outpacing traditional medical interventions. He explains the mechanism of action: “These phages are completely different from viruses that infect humans. They are specifically adapted to infect certain bacteria.” By harnessing these natural predators, Colton aims to create a more effective treatment option in the fight against bacterial infections.

Colton’s journey into this field began with aspirations of becoming a marine biologist. Instead of exploring coral reefs, he found a compelling focus in the microscopic world of bacteria. He describes phages as “the natural control mechanism for all bacteria,” emphasizing their potential role in medical applications.

His startup is currently in the pre-clinical phase, with ongoing animal testing and collaboration with esteemed institutions such as the **Mayo Clinic** and the **OU College of Medicine**. Colton expresses confidence in their progress, stating, “We’re working with some of the biggest players in the market.”

The durability of the phage solution is another advantage. Colton notes that the phages can be stored at room temperature for up to **10 years**, making them a practical option for treatment. He points to petri dishes in his lab that have remained viable for over **two years**, demonstrating their stability.

This innovative approach is particularly personal for Colton, who lost his grandmother due to complications from a post-operative infection. “She just deteriorated,” he recalls. “She went septic because the antibiotics weren’t working, and she passed away.” This loss has fueled his determination to develop effective alternatives to traditional antibiotics.

Paldara Pharmaceuticals received its initial funding of **$21,000** after winning a sales pitch competition at **Oklahoma State University**. As Colton continues to navigate the complexities of developing phage therapy, he remains optimistic about its future. “Turning the page with phage therapy might take years to perfect,” he acknowledges, “but at the age of 26, I have time on my side.”

The potential impact of Paldara Pharmaceuticals extends beyond the lab, promising a new avenue for treatment in an era where superbugs pose significant health risks. As the company advances through its testing phases, it holds the promise of transforming how the medical community addresses bacterial infections.